



Supplemental protein from dairy products increases body weight and vitamin D improves physical performance in older adults: a systematic review and meta-analysis

Dewansingh, P., Melse-Boonstra, A., Krijnen, W. P., van der Schans, C. P., Jager-Wittenaar, H., & van den Heuvel, E. G. H. M.

This is a "Post-Print" accepted manuscript, which has been published in "Nutrition Research"

This version is distributed under a non-commercial no derivatives Creative Commons



(CC-BY-NC-ND) user license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and not used for commercial purposes. Further, the restriction applies that if you remix, transform, or build upon the material, you may not distribute the modified material.

Please cite this publication as follows:

Dewansingh, P., Melse-Boonstra, A., Krijnen, W. P., van der Schans, C. P., Jager-Wittenaar, H., & van den Heuvel, E. G. H. M. (2018). Supplemental protein from dairy products increases body weight and vitamin D improves physical performance in older adults: a systematic review and meta-analysis. *Nutrition Research*, 49, 1-22. DOI: 10.1016/j.nutres.2017.08.004

You can download the published version at:

<https://doi.org/10.1016/j.nutres.2017.08.004>

Title page

Review: Supplemental protein from dairy products increases body weight and vitamin D improves physical performance in older adults: a systematic review and meta-analysis.

Authors: Priya Dewansingh^{1,2,3}, Alida Melse-Boonstra², Wim P. Krijnen^{1, 4}, Cees P. van der Schans^{1, 5, 6, 7} Harriët Jager-Wittenaar^{1, 8}, Ellen G.H.M. van den Heuvel³

Contact information author: Ellen G.H.M. van den Heuvel³

Adres: Post Box 1551, Amersfoort 3800 BN, The Netherlands.

E-mail: ellen.vandenheuvel@frieslandcampina.com

Affiliations

¹ Research Group Healthy Ageing, Allied Health Care and Nursing, Hanze University of Applied Sciences, Groningen, the Netherlands

² Division of Human Nutrition, Wageningen University and Research, the Netherlands.

³ FrieslandCampina, PO Box 1551, 3800 BN, Amersfoort, the Netherlands.

⁴ Faculty of Mathematics and Natural Sciences, University of Groningen, Groningen, the Netherlands.

⁵ Faculty of Medical Sciences, University Medical Center Groningen, Groningen, the Netherlands.

⁶ University of Groningen, University Medical Center Groningen, Dept. Of Rehabilitation Medicine, Groningen, the Netherlands.

⁷ University of Groningen, University Medical Center Groningen, Dept. Of Health Psychology Research, Groningen, the Netherlands.

⁸University of Groningen, University Medical Center Groningen, Dept. of Maxillofacial Surgery, Groningen, the Netherlands.

Abbreviation list

BW body weight

EAA essential amino acids

FFM fat-free mass

FM fat mass

HGS hand grip strength

IU international units

LBM lean body mass

LM lean mass

SMD standard mean difference

TUG timed up and go

1 **Abstract**

2 The purpose of this systematic review and meta-analysis was to assess the effec-
3 tiveness of dairy components on nutritional status and physical fitness in older
4 adults, as evidence for efficacy of the supplementation of these components is in-
5 conclusive. Scopus and MEDLINE were searched. Main inclusion criteria for articles
6 were: double-blind, randomized placebo-controlled trials including participants aged
7 ≥ 55 years who received dairy components or a placebo. Outcome measures were
8 nutrient status (body weight and BMI) and physical fitness (body composition, mus-
9 cle strength, and physical performance). Thirty-six trials with 4,947 participants were
10 included. Most trials investigated protein and vitamin D supplementation and showed
11 no effect on the outcomes. Meta-analysis on the effect of protein on body weight
12 showed a significant increase in mean difference (MD) of 1.13 kg (95% CI: 0.59 to
13 1.67). This effect increased by selecting trials with study a duration of six months in
14 which less nourished and physically fit participants were included. Trials where the
15 participants were (pre-) frail, inactive older adults or when supplementing ≥ 20 grams
16 of protein/day, tended to increase Lean Body Mass (LBM). Only small significant ef-
17 fects of vitamin D supplementation on Timed Up and GO (TUG) (MD -0.75 seconds;
18 95% CI: -1.44 to -0.07) were determined. This effect increased when vitamin D dos-
19 es ranged between 400-1000 IU. Additional large RCT trials of \geq six months are
20 needed regarding the effect of dairy components containing an adequate amount of
21 vitamin D (400-1000 IU) and/or protein (≥ 20 grams) on nutritional status and physical
22 fitness in malnourished or frail older adults.

23

24 **Keywords**

25 Aged, Protein, Vitamin D, nutritional status, Physical fitness

26 **1. Introduction**

27 Malnutrition in older adults is considered to be a serious complication of illness and
28 is associated with increased risks of mortality, longer hospital stays, frequent read-
29 missions [1], and a lower quality of life [2]. Malnutrition can result from starvation,
30 disease, or advanced ageing (e.g. >80 years) and can be experienced alone or in a
31 combination [3]. Moreover, malnutrition can influence the physical fitness, that exists
32 out of body composition, muscle function, and physical function [4]. A decrease in
33 muscle and physical function can pose difficulties in daily activities such as eating
34 [5]. The comprehensive healthcare costs for malnourished institutionalized and
35 community-dwelling older adults in Europe are considerably higher than for well-
36 nourished older adults [6]. Therefore, prevention of malnutrition in the elderly popula-
37 tion is an important strategy for maintaining their quality of life and saving on these
38 costs.

39 Older adults are among the high risk groups for malnutrition [7] for at least two
40 reasons. First, they may have decreased food intake due to “anorexia of ageing”,
41 i.e., a physiologic loss of appetite [8,9] or nutrition impact symptoms caused by ill-
42 ness or medical treatment. For example, difficulties with chewing and swallowing,
43 pain, alterations in taste [10], medication that decreases appetite or increases nutri-
44 ent losses, polypharmacy, dependency on help for consuming meals, and decreased
45 thirst response [11,12] are frequently reported. Second, older adults are more prone
46 to the onset of chronic disease which can activate chronic inflammation [13,14] and
47 consequently result in loss of muscle mass.

48 For older adults, protein requirements can be increased in various situations.
49 For example, when a loss of muscle mass occurs, a high intake of protein is neces-
50 sary to stimulate muscle synthesis [15–17]. In addition to increased protein require-

51 ments, energy requirements may be decreased in older adults mainly due to dimin-
52 ished physical activity and decreased basal metabolic rate during ageing. Nutrient
53 requirements may also possibly increase for older adults [18] such as, discussed for
54 vitamin D [19]. Therefore, this population experiencing unintended weight or appetite
55 loss have an increased risk for nutrient deficiencies.

56 Dairy products can contribute to satisfying the macronutrient and micronutri-
57 ent insufficiencies in the diets of older adults. Various dairy components have been
58 shown to enhance maintenance of bone mass and muscle mass [20–22]. Studies
59 supporting the beneficial effects of milk or dairy products on bone health indicate a
60 significant inverse association between dairy food intake and bone turnover markers
61 and a positive association with bone mineral content [23]. Qualitative evidence is
62 also available for the role of vitamin D and dairy consumption in promoting maximal
63 bone health from childhood through young to late adolescence [24]. In addition to
64 appropriate dietary calcium intake, sufficient serum vitamin D levels are important for
65 skeletal health [25,26]. Vitamin D also stimulates gene expression by involvement in
66 cell development, differentiation, and growth as well as stimulating muscle protein
67 synthesis, and improving strength and balance [27,28].

68 Milk protein consists of whey with a high amount of leucine which has been suggest-
69 ed as being responsible for the enhancing ability to stimulate muscle protein anabo-
70 lism [20,21], which is confirmed by a meta-analysis when combined with physical
71 activity [22]. According to the digestible indispensable amino acid score (DIAAS) of
72 the Food and Agricultural Organization [29], dairy proteins score among the highest
73 in quality even though the presence of leucine was not yet taken into account in this
74 scoring [28]. In a statement from the European Society for Clinical and Economic
75 Aspects of Osteoporosis and Osteoarthritis (ESCEO), the pathways through which

76 dietary protein influences muscle synthesis are either via the activation of mTOR and
77 aromatic amino acids, or via an increase in serum IGF-I. IGF-I can directly affect
78 both muscle synthesis, but also indirectly via vitamin D, as increases in serum IGF-I
79 also stimulates the renal production of 1,25(OH)D₃ (Fig. 1) [30–33]. Via the vitamin
80 D receptors in muscle tissue, 1,25(OH)D₃ contributes to improved balance and
81 physical function. Supplementation has a greater effect on fall risk than on muscle
82 strength [34]. In addition to containing protein, vitamin D, and calcium, (fortified) dairy
83 products are rich in nutrients that are essential for good bone health including zinc,
84 vitamin B12, potassium, and phosphorus [35].

85 Although some evidence for the role of dairy components in physical perfor-
86 mance and bone health seems apparent, there is insufficient knowledge about the
87 effect of dairy components on body composition and muscle strength in older adults.
88 One review states that dairy component protein has a positive effect on muscle mass
89 and strength and that low levels of 25(OH)D are associated with low muscle perfor-
90 mance and postural instability. Additionally, it is stated that the supply of both vitamin
91 D and dietary protein could have a beneficial effect on muscle mass and strength,
92 but mechanisms of interaction remain unclear [30]. Another systematic review of two
93 Randomized Controlled Trials (RCTs) about sarcopenic obese older adults found no
94 effect from 15 gram of protein (through cheese consumption) and no effect from a
95 high-speed circuit resistance training intervention [36]. To the best of our knowledge,
96 there has been no systematic review and meta-analysis that investigated the effec-
97 tiveness of dairy components on nutritional status and physical fitness in healthy
98 older adults, much less in frail or malnourished older adults. Moreover, the quality of
99 most studies is disputable due to the lack of comparison with a placebo and poor
100 randomization, concealment of allocation, and blinding. Therefore, the purpose of

101 this systematic review and meta-analysis was: 1) to review medium-to-high quality
102 trials in order to assess the effectiveness of dairy or dairy components on the nutri-
103 tional status and physical fitness in older adults aged 55 years or older and 2) to
104 identify the most effective treatment based on target groups, intervention duration,
105 and doses, as a basis for future practical recommendations. Our hypothesis is that
106 dairy or dairy components have a beneficial effect on nutritional status and physical
107 fitness in older adults.

108

109 **2. Approach**

110 This systematic review and meta-analyses were performed in accordance to the Pre-
111 ferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guide-
112 lines [37].

113

114

115 **2.1. Search strategy**

116 Relevant studies were searched in the electronic databases of Scopus and PubMed
117 until March 2, 2016. No limits were established for the date of publication and for
118 PubMed, however, the filter humans was activated. A combination of Medical Sub-
119 ject Headings (MeSH) and Boolean operators were used. The most significant key
120 terms that were employed included: aged AND Malnutrition AND "Dairy product*" OR
121 Vitamin D* AND "Body weight" OR "physical perform*" OR Muscles.

122

123

124 **2.2. Inclusion and exclusion criteria**

125 Double-blind, randomized placebo-controlled trials were included when using at least
126 one of the following components present in dairy as an intervention agent: protein,

127 amino acids, calcium, zinc, selenium, iodine, potassium, phosphorus, magnesium,
128 vitamin B2, vitamin B3, vitamin B12, vitamin K, or vitamin D as supplementation in
129 addition to the habitual intake. Sources of the intervention components were not re-
130 strictly dairy-based, however, they should be present in dairy as a component.
131 Studies with a nutritional intervention in addition to exercise were also included.
132 Studies based upon only dietary advice were excluded. The control group was re-
133 quired to receive a placebo tablet or capsule or a 'regular' food product that was
134 compared to the intervention substance. Studies that included 'usual practice' in-
135 stead of a placebo in the control group were excluded. Furthermore, studies of men
136 and women aged 55 years and older who did not have having any type of kidney
137 dysfunction requiring adherence to a protein restricted diet were included in this sys-
138 tematic review and meta-analysis. All inclusion and exclusion criteria are indicated in
139 Table 1.

140

141

142 **2.3. Article eligibility**

143 The title and abstract of every record that was retrieved based on a selection of rele-
144 vant keywords were screened for relevance and eligibility by one reviewer. In addi-
145 tion, reference lists of review articles and articles that underwent full-text selection
146 were screened for other relevant articles. Full-text articles were further assessed for
147 eligibility based on the inclusion and exclusion criteria by two reviewers independent-
148 ly. In the event of uncertainty regarding eligibility of the article or unclear results due
149 to incomplete information, the authors of the article were contacted for additional in-
150 formation. If no clarification was provided after the contact, the trial was excluded

151 from further review, however, when the author provided data, the meta-analysis was
152 adjusted accordingly.

153

154

155 **2.4. Data extraction**

156 Two reviewers extracted the data of the eligible full text articles on the study charac-
157 teristics, i.e., mean age, location of study, the amount, type, and duration of interven-
158 tion, and outcome measurements. When the two reviewers did not agree on a deci-
159 sion, one of the co-authors was asked for an opinion. Final decisions were made by
160 consensus based on the best argument.

161

162

163 **2.5. Quality assessment**

164 The quality of the methodology of the RCTs was also assessed by the two reviewers
165 using the standardized assessment protocol from the Cochrane Collaboration with a
166 score system [38]. A total of 11 criteria were assessed for each study in order to test
167 the internal and external validity (Table 2). Per criteria, a maximum of three points
168 and a minimum of one point could be scored where the maximum score indicated a
169 low risk of bias. Trials that scored the highest points per criteria were selected for an
170 additional meta-analysis that we refer to as a sensitivity analysis.

171

172

173 **2.6. Primary outcome measures**

174 The two main outcome measurements investigated in this systematic review were
175 nutritional status including body weight and BMI and physical fitness, i.e., body com-

176 position, muscle strength, and physical performance. Physical performance includes
177 combinations of walking speed, chair stand, TUG, and balance time [39–43].

178

179

180 **2.7. Meta-, subgroup-, sensitivity analysis and funnel plots**

181 Meta-, subgroup-, sensitivity analyses and funnel plots were performed when at least
182 three studies per outcome measure were found. The data for meta-analyses were
183 either directly extracted from the article as mean difference (MD) values with accom-
184 panied standard deviation for the intervention and control group or calculated sepa-
185 rately for both by subtracting the post-test mean from the baseline mean. Standard
186 deviations of the mean differences not provided by a report were estimated with the
187 use of a within-subject correlation coefficient of 0.5 [44]. Robustness of this assump-
188 tion was tested by applying sensitivity analyses on lower (0.3) and higher (0.8) corre-
189 lation coefficients as well. Meta-analyses were performed in Reman (version 5.3),
190 and data are reported as estimated pooled mean differences with 95% CIs. A p-
191 value of 0.05 or smaller is considered significant for a treatment to be effective in
192 changing the outcome. The sample size of participants was indicated by n while the
193 number of included trials in the meta-analyses was defined as N. For the outcomes
194 ‘physical performance’, ‘walking capacity’, and ‘leg strength’, the standardized mean
195 difference (SMD) was used as the summary statistic in the meta-analyses. SMD was
196 utilized instead of MD when all of the trials assessed the same outcome but meas-
197 ured it by different methods [44]. The SMD expresses the size of the intervention
198 effect per trial relative to the variability observed in that trial [44]. All other results
199 were reported as mean \pm SD unless stated otherwise.

200 We did not restrict the literature search for gender, but recorded this variable
201 as a pre-specified factor for subgroup analyses when applicable. In addition, sub-

202 group analyses were performed on study duration in months; composition of the in-
203 tervention component; intervention dose; several target populations; and exercise
204 training. Sensitivity analyses were conducted based on the risk of bias assessment
205 by only including trials in the analysis that scored the highest points for each risk of
206 bias on each assessment question, which indicates a low risk of bias.

207

208

209 **3. Results**

210 From an initial number of 3,475 articles identified in the search, 36 were included in
211 the systematic review and, of these, 19 were suitable for meta-analyses (Fig. 2). In
212 total, the 36 trials comprised a total number of 4,947 randomized participants ranging
213 from 18 to 1,471 per trial (Table 3). Included trials were carried out in Australia, Bra-
214 zil, Chili, Finland, Iceland, Ireland, Italy, Japan, the Netherlands, Spain, Sweden,
215 Switzerland, and the USA. The trials were conducted in the following settings: vari-
216 ous types of senior citizen care facilities (N=8), hospitals (N=1), fall clinics (N=1),
217 outpatient clinics (N=1), or in the community (N=25).

218 A substantial variety of types of nutritional supplementation was employed in
219 the trials selected for this systematic review. We did not locate any articles regarding
220 the effect of cheese, ice cream, yoghurt, buttermilk, kefir, cultured milk products, se-
221 lenium, iodine, vitamin B2, vitamin B12, phosphorus, potassium, magnesium, vitamin
222 K, Vitamin B3, or zinc. Eighteen trials provided vitamin D supplementation
223 [39,42,43,45–59] of which one provided the intervention group with an extremely low
224 amount of vitamin D of 0.5 µg/day [46]. For this reason, the trial was excluded from
225 all analyses. Fifteen trials used protein as an intervention [40,41,60–72]. A complete
226 overview of all of the included trials and their intervention components is shown in
227 Table 3.

228 Six trials used a factorial design, comparing a nutrition intervention with an
229 exercise-type intervention, using a control activity for exercise (such as watching
230 films, reading, singing and conversation [61,73], visits or phone calls [42], or a social
231 program). In five other trials, participants received a resistance-type exercise training
232 in addition to protein supplementation or a placebo [40,62–64,67].

233

234

235 **3.1. Risk of Bias**

236 Only eight of the 36 trials confirmed proper concealment of allocation, i.e., using
237 sealed envelopes or computer allocation [40–42,50,51,54,62,73]. The quality of the
238 trials was lowest for the criteria blinding of outcome assessors and treatment provid-
239 ers. Details on quality assessment per study are shown in Table 4.

240

241

242 **3.2. Compliance**

243 In 18 trials, compliance was reported to be good ($\geq 80\%$), and the other 18 trials did
244 not report on compliance rate.

245

246

247 **3.3. Nutritional status**

248 One trial investigated the effect of whey protein drinks [60] on nutritional status as
249 assessed by the Mini Nutritional Assessment (MNA) but did not show a significant
250 improvement in MNA score.

251 Fourteen trials investigated the effect of dairy components on body weight;
252 two trials did not publish the summarized data for body weight [42,69], therefore,

253 could not be included in the meta-analysis. Three out of 14 trials ascertained a signif-
254 icant increase in body weight [40,60,69]. An overview of trials included in the sys-
255 tematic review and meta-analysis is depicted in Table 3.

256 Eight trials with either protein or amino acid intervention were included in the
257 meta-analysis on body weight [40,41,60,63–65,67,72]. A significant pooled MD in
258 body weight was found between the protein and placebo group (n=418; MD 1.13 kg;
259 95% CI: 0.59 to 1.67; I²=0%; p<0.0001) (Fig.3).

260 Restricting the meta-analyses to trials wherein a mixture of amino acids as
261 supplementation was provided or excluding trials in which one specific amino acid
262 was given also resulted in a significant body weight increase (n= 330; MD 2.16 kg;
263 95% CI: 0.93 to 3.38; I²=0%; p=0.0006) [40,41,60,63,64]. This was also found when
264 restricting to trials with a duration of at least six months (n=264; MD 2.09 kg; 95% CI:
265 0.88 to 3.29; I²=0%; p=0.0007) [40,41,60,63,65]. Subgroup analyses on four trials
266 that included participants who were at risk of malnutrition, malnourishment [60], or
267 (pre-)frailty [40,41], and those who were bed rest patients and those older than 70,
268 resulted in a substantial increase in body weight with a MD of 1.16 kg; 95% CI: 0.62
269 to 1.71; I²=9%; p=0.0001. Restricting to the five trials in which ≥20 grams of protein
270 per day was supplemented also resulted in a significant increase of body weight (MD
271 1.55 kg; 95%: 0.75 to 2.35; I²=0%; p=0.0001).

272 Finally, restricting to trials that included an exercise training component to
273 both the intervention and control groups or when restricting to trials with sufficient
274 blinding according to the risk of bias assessment resulted in a significant increase of
275 body weight (n=179; MD: 0.78 kg; 95% CI: 0.06 to 1.51; I²=0%; p=0.03, n=235; and
276 MD: 1.18; 95% CI: 0.55 to 1.82; I²=31%; p=0.0003, respectively). The funnel plot,
277 subgroup and sensitivity analyses are shown in Supplemental Figure S1. As indicat-

278 ed in Table 3, nine trials investigated the effect of dairy components on BMI. One out
279 of nine trials reported a significant increase in BMI [69]. In this trial, an amino acid
280 mixture [69] was provided as an intervention.

281

282

283 **3.4 Physical fitness**

284 Only one out of 14 trials determined a significant increase in LBM (Table 3). In that
285 study, protein drinks in combination with resistance-type exercise training were com-
286 pared to a placebo drink combined with exercise training in frail older adults [40].

287 Compared to the other 14 trials, this trial did not specifically differ in intervention du-
288 ration or dose of the supplementation except that they included (pre)frail older adults
289 in their trial while the other studies included well-nourished older adults.

290 A meta-analysis was performed on eight trials (n=474) that investigated pro-
291 tein supplementation [40,62–66,72,74] but did not show an effect in LBM (MD 0.03
292 kg; 95% CI: -0.33 to 0.39; $I^2=0\%$; $p=0.87$) (Fig.4). Restriction to an intervention dura-
293 tion of at least six months resulted in the inclusion of four trials [40,41,63,65] but did
294 not show a significant increase in LBM (n=258; MD 0.40 kg; 95% CI: -1.59 to 2.40;
295 $I^2=0\%$; $p=0.69$). Restriction to trials in which ≥ 20 grams of protein supplementation
296 was given per day, did not result in a significant increase in LBM (n= 221; MD of 0.60
297 kg; 95% CI: -0.09 to 1.29; $I^2=0\%$; $p=0.09$) [40,41,63,72]. When including trials with
298 (pre-) frail older adults [40,41] and compulsorily inactive older adults [72], the in-
299 crease of LBM was inconsequential (n=141; MD: 0.61 kg; 95% CI: -0.09 to 1.31;
300 $I^2=0\%$; $p=0.09$). Finally, subgroup analyses including trials that intervened with pro-
301 tein supplementation as well as exercise showed no beneficial effect (n=303; MD -
302 0.18 kg; 95% CI: -0.61 to 0.26; $I^2=0\%$; $p=0.42$) [40,62–64].

303 None of the four trials investigating the effect of protein on regional leg LBM
304 showed a significant difference between the intervention and placebo group. One
305 trial investigated the effect of β -Hydroxy-Methyl butyrate (HMB), arginine, and lysine
306 supplementation [70] on FFM but failed to find a significant effect. One trial investi-
307 gated the effect of vitamin D on regional FFM, but the summarized data and result
308 were not published [45]. Another study investigated the effect of six months of sup-
309 plementation with a protein drink on skeletal muscle index but did not show a con-
310 siderable difference between the intervention and placebo group [60].

311 Thirteen trials investigated the effect of dairy components or vitamin D on total
312 or regional fat mass. One out of the eight studies showed a significant increase in
313 favor of protein supplementation on fat mass and found a substantial increase in fa-
314 vor of protein [40]. One trial providing calcium supplementation reported a significant
315 decrease in fat mass in the active absorbable algal calcium (AAACa) group (but not
316 in the calcium carbonate group) compared to the placebo group [75]. Trials investi-
317 gating the effect of leucine supplementation on leg fat mass [65,66] did not show a
318 meaningful difference between the intervention and placebo groups over time. The
319 one trial investigating the effect of vitamin D on regional fat mass did not publish the
320 summarized data on regional fat mass but reported that the change in fat mass was
321 not significant [45].

322 One out of the three trials investigated the effect of dairy components on fat
323 mass on calf, arm, waist, hip, trunk, and limb circumference or waist-to-hip ratio
324 [42,67,70] and revealed a significant effect of HMB, arginine, and lysine on calf, trunk
325 and limb circumference [70].

326 Five trials investigated the effect of protein supplementation and vitamin D on
327 the fiber cross-sectional area (Table 3). A significant increase in total (combined type

328 I and type II) fiber cross-sectional area (FCSA) was found in only one trial in which
329 vitamin D3 was supplemented [39]. Another trial confirmed the effect of vitamin D2
330 on type II fiber diameter (mean percentage change of $96.5\% \pm 26.7\%$; $-22.5\% \pm 6.7\%$,
331 $p < 0.0001$, respectively). The other three trials investigated the effect of protein sup-
332 plementation but did not show a significant effect [41,65,66].

333 Table 3 indicates that 20 trials investigated the effect of dairy components and
334 vitamin D on leg strength. Two of the 20 trials reported a significant increase in (left)
335 leg strength in participants receiving vitamin D3 supplementation. These trials were
336 different from the other studies as they included long-stay geriatric care residents
337 who were given 800 IU per day [51] instead of 400 IU or high doses of vitamin D3 on
338 monthly basis (150,000 IU once a month during the first two months followed by
339 90,000 IU once a month for the last four months) [50]; a greater number of partici-
340 pants ($n=242$) [52] and a longer study duration of 12 months [52].

341 Six trials that investigated vitamin D supplementation were included in the
342 meta-analyses [42,48,49,52,57] which showed no significant effect of vitamin D on
343 leg strength ($n=735$; SMD 0.09; 95% CI: -0.05 to 0.24; $I^2=0\%$; $p=0.22$, Fig.
344 5). Selecting trials with vitamin D doses between 1000 to 4000 IU did not result in an
345 indication of a significant increase of leg strength ($n=345$; SMD 0.04; 95% CI -0.17 to
346 0.26; $I^2=1\%$; $p=0.69$). When restricting to trials with a study duration of at least six
347 months, no significant increase of leg strength was found ($n=711$; SMD 0.08; 95% CI
348 -0.07 to 0.22; $I^2=0\%$; $p=0.31$). When excluding studies with high loss to follow up, a
349 significant increase in leg strength did not occur with a vitamin D supplementation
350 ($n=380$; SMD 0.08; 95% CI: -0.07 to 0.22; $I^2=0\%$; $p=0.31$) [42,49,52]. With a re-
351 striction to trials with comparable baseline characteristics in the intervention and con-

352 trol groups, an increase in leg strength also did not occur with a vitamin D supple-
353 mentation (n=581; SMD 0.13; 95% CI: -0.07 to 0.33; I²=0%; p=0.19) [42,48,52,57].

354 For the meta-analysis on six trials in which protein supplementation took place
355 [40,41,62–65], there was no significant effect on leg strength (n=417; SMD 0.05;
356 95% CI: -0.14 to 0.24; I²=0%; p=0.60, Fig. 6). Furthermore, no significant effect on
357 leg strength was found after limiting to four trials that used six months of protein sup-
358 plementation (n= 193; SMD 0.05; 95% CI: -0.20 to 0.30; I²=0%; p=0.68)
359 [40,41,63,65] nor when restricting to trials with protein supplementation of at least 20
360 gram per day (n=193; SMD 0.05; 95% CI -0.23 to 0.34; I²=0%; p=0.71).

361 Two trials investigated the effect of vitamin D3 and calcium on ankle dorsiflex-
362 ion, hip abductor, hip extensor hip adductor [57], and hip flexor [50,57]. One trial did
363 not publish the data or only reported the significance of the results [50]. One trial
364 showed a significant increase in hip extensor (vitamin D group: 5.2±0.7 kg versus
365 placebo group: 3.1±0.8 SE kg,) and hip adductor strength (vitamin D group: 3.4±0.5
366 and placebo group: 2.1±0.6) when compared to the lowest tertile for hip extensor
367 (≤11 kg) and for hip adductor (≤12 kg) [57].

368 Eight trials studied the effect of dairy components and vitamin D on hand grip
369 strength (Table 3). One trial did not publish the summarized data or significance for
370 hand grip strength [71]. Four trials with vitamin D intervention were included in order
371 to perform a meta-analysis with the outcome hand grip strength [42,48,49]. Two trials
372 studied a daily dose of 400 IU vitamin D3 [42], and the other trial studied the effect of
373 1000 IU vitamin D3 [49]. For one trial, we compared vitamin D and no training with a
374 placebo and no training (Bunout 2006-A) but also vitamin D and training with a pla-
375 cebo and training (Bunout 2006-B) [42].

376 Meta-analysis showed a non-significant MD of 0.40 kg; 95% CI: -1.11 to 1.92;
377 $I^2=0\%$; $p= 0.60$ (Fig. 7) ($n=222$ participants). For the sensitivity analysis, a meta-
378 analysis was performed separately for trials with a low loss to follow-up, however, no
379 significant increase of hand grip strength due to vitamin D supplementation was
380 found (MD 0.52 kg; 95% CI: -12 to 2.15; $I^2=0\%$; $p=0.54$).

381 Table 3 depicts that seven trials investigated the effect of dairy components
382 and vitamin D on physical performance. Two of the seven trials studying the effect of
383 protein drinks or vitamin D found a significant effect when compared to the placebo
384 group [41,54]. These two trials differed with the other trials by including participants
385 who were vitamin D deficient and attending a fall clinic or (pre-)frail older adults
386 [40,54]. The other eight trials did not find significant improvement in physical
387 performance.

388 A total of four trials supplying vitamin D were included in the meta-analysis
389 (Fig. 8). No effect from vitamin D supplementation on physical performance was
390 found (SMD 0.12; 95% CI: -0.07 to 0.30; $I^2=57\%$; $p=0.22$). A subgroup analysis was
391 performed based on restricting to trials that gave vitamin D3 supplementation. How-
392 ever, no significant effect was determined (SMD 0.12; 95% CI: -0.07 to 0.31; $I^2=67\%$;
393 $p=0.21$). The funnel plot on physical performance showed a small asymmetry, indi-
394 cating possible weak publication bias (Supplemental figure S8).

395 Ten trials investigated the effect of dairy components and vitamin D on walk-
396 ing capacity (Table 3). One study investigated with participants walking 50 feet but
397 did not publish the summarized data or results [54]. Only one of the 15 remaining
398 trials showed a significant increase in walking capacity as measured by the six
399 minute walking test [71]. This study investigated the effect of a 12 gram amino acid
400 mixture (L-leucine, L-lysine, L-isoleucine, L-valine, L-threonine, L-cysteine, L-

401 histidine, L-phenylalanine, L-methionine, L-tyrosine, and L- tryptophan) per day
402 compared to a placebo in a healthy elderly population for three months. Meta-
403 analysis was performed on three trials that investigated the effect of vitamin D
404 supplementation on walking capacity (Fig.9). The SMD was 0.04; 95% CI: -0.17 to
405 0.24; $I^2=0\%$; $p=0.73$. The funnel plot showed no signs of publication bias.

406 Eight trials investigated the effect of dairy components or vitamin D on the
407 timed chair stands (Table 3). Two trials did not report the effect size or the p-value of
408 the duration of the chair stand [43,54]. Only one of the remaining seven trials
409 showed a significant change in the duration of the timed chair stand using chairs that
410 differed in height (36 cm, 47 cm and 53 cm). The test with the shortest chair showed
411 a significantly higher score for the intervention group compared to the placebo group.
412 This significant result was not found for the tallest chair [53]. The other trials did not
413 report the height of the chair.

414 Four trials investigated the effect of dairy components and vitamin D on bal-
415 ance (Table 3). Two trials did not report the summarized data or result [41,61]. The
416 remaining trials did not show a substantial difference between the intervention and
417 placebo group over time [49,73].

418 Table 3 shows that ten trials investigated the effect of dairy components or
419 vitamin D on TUG. However, in one trial, no data or description of significance was
420 provided (37). Only two of the remaining nine trials found a significant effect of vita-
421 min D or protein supplementation on TUG [57,70]. Six trials with vitamin D
422 supplementation were included in a meta-analysis [42,48,49,52,56,57]. These six
423 trials gave vitamin D3 [42,48,49,52] or vitamin D2 [56,57]. One trial used a 2x2 facto-
424 rial design with an exercise intervention and a control activity [42]. Meta-analysis
425 showed a significantly decreased MD of -0.75 seconds; 95% CI: -1.44 to -0.07

426 seconds; $I^2=0\%$; $p=0.03$ (Fig. 10).

427 A significant effect on TUG was found after limiting to trials that used a daily
428 vitamin D dose of 400-1000 IU ($N=5$; $n=711$; MD -0.81 seconds; 95% CI: -1.51 to -
429 0.11; $I^2=0\%$; $p=0.02$) [42,48,49,52,57] (Supplemental Figure S9). No significant ef-
430 fect was found after limiting the analysis to trials that included vitamin D3 as a sup-
431 plement: MD -0.70; 95% CI: -1.52 to 0.12; $I^2=0\%$; $p=0.10$ [42,48,49,52]. The sensitiv-
432 ity analysis was limited to trials with a low loss to follow-up [42,49,52,56]. It did not
433 show a significant difference between intervention and placebo groups, MD -0.62;
434 95% CI: -1.44 to 0.20; $I^2=0\%$; $p=0.14$.

435

436

437 **4. Discussion**

438 This systematic review and meta-analysis showed that the dairy components protein
439 and vitamin D have beneficial effects for older adults. Protein supplementation
440 increased body weight by 1.13 kg, and vitamin D supplementation increased
441 physical fitness, measured as TUG improvement by 0.75 seconds. However, the
442 majority of the trials found no effect on nutritional status or physical fitness from sup-
443 plementation with dairy components. No studies were determined to examine the
444 effects of specific dairy products on any of the investigated outcomes. Leg strength
445 was the most frequently studied outcome, i.e., in 20 studies, followed by body weight
446 in 14 studies. The least studied outcome was hip muscle strength (two studies).

447 The significant effect of protein supplementation on body weight found in this
448 meta-analysis confirmed results from two earlier meta-analyses which showed an
449 increase in body weight of 2.15 kg (95% CI: 1.80 to 2.49 [76] and 1.02 kg (95% CI:
450 0.19 to 1.85) [77] due to protein-energy and leucine supplementation. The greater

451 increase in body weight found in one meta-analysis [76] can be explained by the
452 amount of protein-energy supplementation in the included studies which ranged from
453 175 to 1350 kcal/day compared to a maximal amount of 313 kcal/day provided in the
454 trials included in our meta-analysis. This indicates that a larger amount of energy
455 and protein is required in the event that more weight gain is warranted such as in the
456 elderly that are more frail. When we restricted the current meta-analysis to studies
457 that provided ≥ 20 -grams protein per day, this resulted in an increased change in
458 body weight (MD) from 1.13 kg to 1.55 kg. Substantial effects on body weight were
459 also observed when restricting to studies of longer duration (MD 2.09 kg) or when a
460 mixture of amino acids (MD 2.16 kg) was given. Similar results were found when re-
461 stricting to studies including older adults >70 years of age, those at risk for malnutri-
462 tion, or those who were already malnourished, (pre-) frail, or compulsory inactive
463 (MD 1.16). When restricting to trials that combined protein supplementation and ex-
464 ercise training, a significant change in body weight was found, although with a
465 smaller effect size of 0.76 kg.

466 In our systematic review, no effect from protein supplementation on physical
467 fitness, measured by body composition components (e.g. LBM), muscle strength, or
468 physical performance was ascertained. A potential explanation of the absence of
469 significant results of protein on body composition measures by meta-analyses might
470 be poor compliance. Although most trials did not report on the compliance rate, we
471 found that protein intake in 50% of the individual trials of the current meta-analysis
472 did not significantly differ from baseline in the protein group at follow-up. This indi-
473 cates that the compliance was low and that the effect of protein supplementation was
474 not properly investigated. Moreover, in two trials, both the intervention and control
475 groups had already complied with the daily protein intake guidelines [64,65] which

476 might not provide the opportunity to increase LBM by postprandial muscle protein
477 synthesis. To achieve stimulation of muscle protein synthesis, an amount of 20-30
478 grams of protein per meal has been suggested as being required for sufficient stimu-
479 lation of postprandial muscle synthesis [41,78]. This was partly confirmed in our sys-
480 tematic review; restriction to trials that supplemented ≥ 20 grams of protein per day or
481 to trials which included (pre-) frail or compulsory inactive older adults resulted in a
482 tendency towards an increase in LBM of 0.61 kg ($p=0.09$).

483 We investigated the effect of the supplementation of dairy components on
484 FFM; however, a meta-analysis was not possible due to a low number of trials. In
485 contrast to other meta-analyses and systematic reviews [22,79], we found no signifi-
486 cant effect of protein supplementation on FFM. Cermak et al.[22] reported a pooled
487 estimate of a 0.48 kg (95% CI: 0.10 to 0.85) increase in FFM due to protein supple-
488 mentation during prolonged resistance-type exercise training in healthy older adults.
489 This finding is in accordance with a review that states that resistance training in
490 combination with dietary protein or amino acids or protein supplementation has a
491 positive effect on muscle strength, muscle mass, and also physical function in older
492 adults [17]. Cermak et al.[22]included studies that did not apply to our two inclusion
493 criteria regarding age which were being younger (aged 18 years and older) and the
494 obligation of using a placebo as a control [80]. Our stricter inclusion criteria hindered
495 us in including an adequate number of trials for a meta-analysis with FFM as out-
496 come and, therefore, sufficient power to detect any possible significant differences.
497 The trial without a placebo [80] indicated a substantial increase in muscle mass and
498 was also included in the other positive systematic review[79].

499 We found that the effect of vitamin D supplementation on TUG improved more
500 profoundly when restricted to trials that provided a dose of 400-1000 IU (MD: -0.81

501 seconds; $p=0.02$). The actual proper dose of vitamin D supplementation is currently
502 under discussion [81]. One trial found no effect of high monthly doses of 60.000 IU
503 (2000 IU/d) vitamin D calcifediol on lower extremity function in older adults compared
504 to a reference dose of 24.000 (800 IU/d) [81]. Their subgroup analysis even revealed
505 that participants reaching elevated 25(OH)D levels between 111.8-247.3 nmol/L had
506 the greatest chances of falling and had the most falls compared to participants with
507 levels between 53.3-75.8 nmol/L [81]. Another systematic review states that a daily
508 dose of at least 800 IU is required to improve muscle strength [82]. Unfortunately,
509 there were too few trials to do a subgroup analysis on a specific daily dose such as
510 800 IU or doses of vitamin D higher than 1000 IU per day. However, according to our
511 meta-analysis, a regimen of dosing towards a daily dose of 400 to 1000 IU seems to
512 be beneficial with a small reduction in TUG.

513 Our systematic review and meta-analysis have several strengths and limita-
514 tions. A major strength is the strict selection criteria for the trials which only allowed
515 randomized controlled trials that used a placebo and that had applied double blinding
516 to ensure a high level of evidence due to a lower risk of bias. A second strength is
517 the small degree of heterogeneity, indicated by I^2 , in the meta-analysis which makes
518 comparison between trials reliable. Third, although the abstract and title selection
519 were decided by one reviewer, the full text selection of articles was done carefully by
520 two independent reviewers. Fourth, we performed funnel plots to assess possible
521 publication bias and most of these showed no concern for it. The funnel plot on phys-
522 ical performance showed a small asymmetry, indicating possible weak publication
523 bias. In addition to publication bias, we assessed the risk of bias per trial. Although
524 the quality of studies could have been improved by more effective blinding of out-

525 come assessors and treatment providers, the quality of included trials scored rather
526 well since the inclusion criteria were strict.

527 The first limitation of our systematic review and meta-analysis is that we could
528 not draw a conclusion about the effect of specific dairy products on the outcomes of
529 nutrient status or physical fitness, because studies where the intervention existed out
530 of dairy products instead of only dairy components were not available. Second, the
531 majority of the trials did not publish the mean change with its accompanying stand-
532 ard deviation nor the correlation coefficient which describes the association between
533 baseline and final measurements across participants [44]. Another meta-analysis
534 estimated a correlation coefficient of 0.98 for FFM, and 0.70 (protein) and 0.80 (pla-
535 cebo) for one repetition maximum (1-RM) strength based on trials in healthy younger
536 (<50 yrs. old) and older participants (>50 yrs. old) [22]. We estimated the standard
537 deviation change, by using a conservative correlation coefficient of 0.5 [83]. Howev-
538 er, a sensitivity analysis of different correlation coefficients showed that using a cor-
539 relation coefficient of 0.8 resulted in a significantly increased LBM due to protein.
540 Similarly, a significant effect was found of vitamin D3 (excluding trials that supple-
541 mented vitamin D2) on TUG as well as when selecting trials that had a low loss of
542 follow-up when applying a correlation coefficient of 0.8. Therefore, we may have un-
543 derestimated these effects. It would be beneficial if future scientific papers present
544 the actual mean change with its accompanying standard deviations to enable more
545 meta-analyses that are accurate and allow for higher levels of scientific evidence. A
546 third limitation is that we included trials in which resistance-type exercise training
547 was given to both the nutritional intervention and the control groups in order to in-
548 crease the number of included trials and, therefore, statistical power. However, we
549 do not have information on the interaction of the nutritional intervention and the exer-

550 cise training. Therefore it is not possible to differentiate the effect between the nutri-
551 tional intervention and interaction with the exercise component. However, a meta-
552 analysis did not show an increase in heterogeneity with the trials that included an
553 exercise component. A fourth limitation is the rather low number of studies included,
554 especially for the meta-,subgroup, and sensitivity analysis. This hampered a robust
555 effect estimate for older adults who were more vulnerable and gender specific con-
556 clusions whereas others stated that protein and vitamin D supplementation have a
557 beneficial effect on target groups who were malnourished, vitamin D deficient, or frail
558 [41,81,84]. The next limitation was the extensive number of outcome measurements
559 used in included studies to examine body composition and physical fitness. Uniformi-
560 ty in outcome measurements is important for delivering high quality evidence based
561 on meta-analyses, and it brings more focus to practical advice for the health care
562 setting. Finally, we had a low response rate on our attempts to contact authors to
563 request missing or additional details on their published data.

564

565

566 **5. Conclusion**

567 Most of the trials included in this systematic review showed no effect of dairy com-
568 ponents that were provided in addition to the habitual intake on nutritional status and
569 physical fitness. However, based on the current meta-analysis, we conclude that
570 protein supplementation increases body weight. This effect was greater after select-
571 ing trials with a study duration of six months and when participants were at risk for
572 malnutrition, malnourished, or (pre-)frailty, were bed rest patients, or were older than
573 70 years. The increase in body weight tended to be explained by differences in LBM
574 but only when supplementing doses of protein higher than 20 g/d or when giving pro-

575 tein supplementation to (pre-) frail or compulsorily inactive older adults. In addition,
576 the meta-analysis showed that vitamin D can improve physical performance as
577 assessed by TUG in older adults. No other beneficial effect of dairy components on
578 muscle strength, hand grip strength, overall physical performance, walking capacity,
579 or balance could be substantiated in this systematic review and meta-analysis.
580 Publication bias was nearly nonexistent, and heterogeneity between trials was
581 minimal.

582

583

584 **6. Recommendations for future research**

585 More double-blind, randomized placebo-controlled trials should be undertaken in frail
586 or malnourished older adults instead of healthy community-dwelling older adults. The
587 effect of additional dairy components seems to be of little clinical relevance in
588 healthy older adults but appears to be higher older adults that are more vulnerable.
589 Additionally, doses of 400-1000 IU of vitamin D supplementation seem beneficial for
590 physical performance, but supplementation doses of 800 IU are hypothesized to be
591 more beneficial than 400 IU for muscle strength [77]. Therefore, future research
592 should focus on doses of approximately 800 IU in order to test this hypothesis. Final-
593 ly, the combination of dairy components in one intervention should be studied to see
594 if the combination of adequate vitamin D and protein is more effective than either of
595 them alone.

596

597

598 **7. Acknowledgments**

599 This work was supported by FrieslandCampina. First author (Dewansingh) was an
600 intern at FrieslandCampina until August 31st, 2015. Author Van den Heuvel is an
601 employee at FrieslandCampina. Other co-authors have no conflict of interest.

602 We would like to thank Manon Galama for her contribution in the article selection and
603 data extraction.

604

605

606 **8. Reference list**

- 607 [1] Correia MITD, Hegazi RA, Higashiguchi T, Michel JP, Reddy BR, Tappenden
608 KA, et al. Evidence-based recommendations for addressing malnutrition in
609 health care: An updated strategy from the feedM.E. global study group. *J Am*
610 *Med Dir Assoc* 2014;15:544–50. doi:10.1016/j.jamda.2014.05.011.
- 611 [2] Rasheed S, Woods RT. Malnutrition and quality of life in older people: a
612 systematic review and meta-analysis. *Ageing Res Rev* 2013;12:561–6.
613 doi:10.1016/j.arr.2012.11.003.
- 614 [3] Pirlich M, Schütz T, Kemps M, Luhman N, Minko N, Lübke HJ, et al. Social risk
615 factors for hospital malnutrition. *Nutrition* 2005;21:295–300.
616 doi:10.1016/j.nut.2004.06.023.
- 617 [4] Pate RR. The evolving definition of physical fitness. *Quest* 1988;40:174–9.
618 doi:10.1080/00336297.1988.10483898.
- 619 [5] Volkert D. The role of nutrition in the prevention of sarcopenia. *Wien Med*
620 *Wochenschr* 2011;161:409–15. doi:10.1007/s10354-011-0910-x.
- 621 [6] Abizanda P, Sinclair A, Barcons N, Lizán L, Rodríguez-Mañas L. Costs of
622 Malnutrition in Institutionalized and Community-Dwelling Older Adults: A
623 Systematic Review. *J Am Med Dir Assoc* 2016;17:17–23.
624 doi:10.1016/j.jamda.2015.07.005.
- 625 [7] Donini LM, Scardella P, Piombo L, Neri B, Asprino R, Proietti AR, et al.
626 Malnutrition in elderly: Social and economic determinants. *J Nutr Heal Aging*
627 2013;17:9–15. doi:10.1007/s12603-012-0374-8.
- 628 [8] Visvanathan R. Under-nutrition in older people: A serious and growing global
629 problem! *J Postgrad Med* 2003;49:352–60.

- 630 [9] Donini LM, Savina C, Piredda M, Cucinotta D, Fiorito A, Inelmen EM, et al.
631 Senile anorexia in acute-ward and rehabilitation settings. *J Nutr Heal Aging*
632 2008;12:511–7. doi:10.1007/BF02983203.
- 633 [10] Vissink A, Jansma J, Spijkervet FKL, Burlage FR, Coppes RP. Oral sequelae
634 of head and neck radiotherapy. *Crit Rev Oral Biol Med* 2003;14:199–212.
635 doi:10.1177/154411130301400305.
- 636 [11] Avenell A HH. Nutritional supplementation for hip fracture aftercare in older
637 people. *Cochrane Database Syst Rev* 2007;1.
- 638 [12] McMurdo MET, Price RJG, Shields M, Potter J, Stott DJ. Should oral
639 nutritional supplementation be given to undernourished older people upon
640 hospital discharge? A controlled trial. *J Am Geriatr Soc* 2009;57:2239–45.
641 doi:10.1111/j.1532-5415.2009.02568.x.
- 642 [13] Ingenbleek Y, Bernstein L. The stressful condition as a nutritionally dependent
643 adaptive dichotomy. *Nutrition* 1999;15:305–20. doi:10.1016/S0899-
644 9007(99)00009-X.
- 645 [14] Norman K, Pichard C, Lochs H, Pirlich M. Prognostic impact of disease-related
646 malnutrition. *Clin Nutr* 2008;27:5–15. doi:10.1016/j.clnu.2007.10.007.
- 647 [15] Houston DK, Nicklas BJ, Ding J, Harris TB, Tylavsky FA, Newman AB, et al.
648 Dietary protein intake is associated with lean mass change in older,
649 community-dwelling adults: the Health, Aging, and Body Composition (Health
650 ABC) Study. *Am J Clin Nutr* 2008;87:150–5. doi:87/1/150 [pii].
- 651 [16] Mithal A, Bonjour JP, Boonen S, Burckhardt P, Degens H, El Hajj Fuleihan G,
652 et al. Impact of nutrition on muscle mass, strength, and performance in older
653 adults. *Osteoporos Int* 2013;24:1555–66. doi:10.1007/s00198-012-2236-y.

- 654 [17] Naseeb MA, Volpe SL. Protein and exercise in the prevention of sarcopenia
655 and aging. *Nutr Res* 2017;40:1–20. doi:10.1016/j.nutres.2017.01.001.
- 656 [18] ter Borg S, Verlaan S, Mijnders DM, Schols JMGA, de Groot LCPGM,
657 Luiking YC. Macronutrient Intake and Inadequacies of Community-Dwelling
658 Older Adults, a Systematic Review. *Ann Nutr Metab* 2015;66:242–55.
- 659 [19] EFSA. Scientific Opinion on Dietary Reference Values for vitamin D1 2 EFSA
660 Panel on Dietetic Products, Nutrition, and Allergies (NDA). 2016.
- 661 [20] Garlick PJ. The role of leucine in the regulation of protein metabolism. *J Nutr*
662 2005;135:1553S–6S. doi:10.1093/ajph/135/6/1553S [pii].
- 663 [21] Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high
664 proportion of leucine is required for optimal stimulation of the rate of muscle
665 protein synthesis by essential amino acids in the elderly. *Am J Physiol*
666 *Endocrinol Metab* 2006;291:E381–7. doi:10.1152/ajpendo.00488.2005.
- 667 [22] Cermak NM, Res PT, De Groot LCPGM, Saris WHM, Van Loon LJC. Protein
668 supplementation augments the adaptive response of skeletal muscle to
669 resistance-type exercise training: A meta-analysis. *Am J Clin Nutr*
670 2012;96:1454–64. doi:10.3945/ajcn.112.037556.
- 671 [23] Rizzoli R. Dairy products, yogurts, and bone health. *Am J Clin Nutr* 2014;99.
672 doi:10.3945/ajcn.113.073056.
- 673 [24] Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. The
674 National Osteoporosis Foundation’s position statement on peak bone mass
675 development and lifestyle factors: a systematic review and implementation
676 recommendations. *Osteoporos Int* 2016;27:1281–386. doi:10.1007/s00198-
677 015-3440-3.

- 678 [25] Avenell A, Mak JCS, O'Connell D. Vitamin D and vitamin D analogues for
679 preventing fractures in post-menopausal women and older men. *Cochrane*
680 *Database Syst Rev* 2014;CD000227. doi:10.1002/14651858.CD000227.pub4.
- 681 [26] Lips P, Gielen E, van Schoor NM. Vitamin D supplements with or without
682 calcium to prevent fractures. *Bonekey Rep* 2014;3:512.
683 doi:10.1038/bonekey.2014.7.
- 684 [27] Ceglia L, Harris SS. Vitamin D and its role in skeletal muscle. *Calcif Tissue Int*
685 2013;92:151–62. doi:10.1007/s00223-012-9645-y.
- 686 [28] Wolfe RR. Update on protein intake: importance of milk proteins for health
687 status of the elderly. *Nutr Rev* 2015;73:41–7. doi:10.1093/nutrit/nuv021.
- 688 [29] FAO. Dietary protein quality evaluation in human nutrition: Report of an FAO
689 expert consultation 2011. [http://www.fao.org/ag/humannutrition/35978-](http://www.fao.org/ag/humannutrition/35978-02317b979a686a57aa4593304ffc17f06.pdf)
690 [02317b979a686a57aa4593304ffc17f06.pdf](http://www.fao.org/ag/humannutrition/35978-02317b979a686a57aa4593304ffc17f06.pdf) (accessed April 21, 2016).
- 691 [30] Bonjour J-P, Kraenzlin M, Levasseur R, Warren M, Whiting S. Dairy in
692 adulthood: from foods to nutrient interactions on bone and skeletal muscle
693 health. *J Am Coll Nutr* 2013;32:251–63. doi:10.1080/07315724.2013.816604.
- 694 [31] Rizzoli, J.C. Steverson, J.M. Bauer, L.J.C. van Loon, S. Walrand, J.A.
695 Kanis, C. Cooper, M.L. Brandi, A. Diez-Perez O. The role of dietary protein and
696 vitamin D in maintaining musculoskeletal health in postmenopausal women: A
697 consensus statement from the European Society for Clinical and Economic
698 Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Maturitas* 2014;79:122–
699 32.
- 700 [32] Campbell WW. Synergistic use of higher-protein diets or nutritional
701 supplements with resistance training to counter sarcopenia. *Nutr Rev*

- 2007;65:416–22. doi:10.1301/nr.2007.sept.416.
- [33] Pasiakos SM. Exercise and amino acid anabolic cell signaling and the regulation of skeletal muscle mass. *Nutrients* 2012;4:740–58. doi:10.3390/nu4070740.
- [34] Dawson-Hughes B. Vitamin D and muscle function. *J Steroid Biochem Mol Biol* 2017;1–4. doi:10.1016/j.jsbmb.2017.03.018.
- [35] van Staveren WA, de Groot LCPGM. Evidence-based dietary guidance and the role of dairy products for appropriate nutrition in the elderly. *J Am Coll Nutr* 2011;30:429S–37S. doi:10.1080/07315724.2011.10719987.
- [36] Theodorakopoulos C, Jones J, Bannerman E, Greig CA. Effectiveness of nutritional and exercise interventions to improve body composition and muscle strength or function in sarcopenic obese older adults: A systematic review. *Nutr Res* 2017;43:3–15. doi:10.1016/j.nutres.2017.05.002.
- [37] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int J Surg* 2010;8:336–41. doi:10.1016/j.ijsu.2010.02.007.
- [38] Higgins JPT AD. Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). *Cochrane Handbook for systematic Reviews of Interventions*. Version 5.1.0 [updated March 2011]. Cochrane Collab 2011.
- [39] Ceglia L, Niramitmahapanya S, da Silva Morais M, Rivas DA, Harris SS, Bischoff-Ferrari H, et al. A randomized study on the effect of vitamin D₃ supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. *J Clin Endocrinol Metab* 2013;98:E1927-35. doi:10.1210/jc.2013-2820.

- 726 [40] Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot
727 LCPGM, et al. Protein supplementation increases muscle mass gain during
728 prolonged resistance-type exercise training in frail elderly people: a
729 randomized, double-blind, placebo-controlled trial. *J Am Med Dir Assoc*
730 2012;13:713–9. doi:10.1016/j.jamda.2012.05.020.
- 731 [41] Tieland M, van de Rest O, Dirks ML, van der Zwaluw N, Mensink M, van Loon
732 LJC, et al. Protein supplementation improves physical performance in frail
733 elderly people: a randomized, double-blind, placebo-controlled trial. *J Am Med*
734 *Dir Assoc* 2012;13:720–6. doi:10.1016/j.jamda.2012.07.005.
- 735 [42] Bunout D, Barrera G, Leiva L, Gattas V, De La Maza MP, Haschke F, et al.
736 Effect of a nutritional supplementation on bone health in chilean elderly
737 subjects with femoral osteoporosis. *J Am Coll Nutr* 2006;25:170–7.
- 738 [43] Lips P, Binkley N, Pfeifer M, Recker R, Samanta S, Cohn DA, et al. Once-
739 weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on
740 neuromuscular function and tolerability in older adults with vitamin D
741 insufficiency. *Am J Clin Nutr* 2010;91:985–91. doi:10.3945/ajcn.2009.28113.
- 742 [44] The Cochrane Collaboration. *Cochrane Handbook for Systematic Reviews of*
743 *Interventions* Version 5.1.0 [updated March 2011]. 2011. doi:Available from
744 www.cochrane-handbook.org.
- 745 [45] Gallagher JC, Yalamanchili V, Smith LM. The effect of vitamin D
746 supplementation on serum 25(OH)D in thin and obese women. *J Steroid*
747 *Biochem Mol Biol* 2013;136:195–200. doi:10.1016/j.jsbmb.2012.12.003.
- 748 [46] Grady D, Halloran B, Cummings S, Leveille S, Wells L, Black D, et al. 1,25-
749 dihydroxyvitamin D3 and muscle strength in the elderly: A randomized

- 750 controlled trial. *J Clin Endocrinol Metab* 1991;73:1111–7.
- 751 [47] Dawson-Hughes B, Dallal GE, Krall EA, Harris S, Sokoll LJ, Falconer G. Effect
752 of vitamin D supplementation on wintertime and overall bone loss in healthy
753 postmenopausal women. *Ann Intern Med* 1991;115:505–12. doi:10.7326/0003-
754 4819-115-7-505.
- 755 [48] Janssen HCJP, Samson MM, Verhaar HJJ. Muscle strength and mobility in
756 vitamin D-insufficient female geriatric patients: A randomized controlled trial on
757 vitamin D and calcium supplementation. *Aging Clin Exp Res* 2010;22:78–84.
- 758 [49] Kenny AM, Biskup B, Robbins B, Marcella G, Burleson JA. Effects of Vitamin
759 D Supplementation on Strength, Physical Function, and Health Perception in
760 Older, Community-Dwelling Men. *J Am Geriatr Soc* 2003;51:1762–7.
761 doi:10.1046/j.1532-5415.2003.51561.x.
- 762 [50] Moreira-Pfrimer LDF, Pedrosa MAC, Teixeira L, Lazaretti-Castro M. Treatment
763 of vitamin D deficiency increases lower limb muscle strength in institutionalized
764 older people independently of regular physical activity: a randomized double-
765 blind controlled trial. *Ann Nutr Metab* 2009;54:291–300.
766 doi:10.1159/000235874.
- 767 [51] Bischoff HA, Stähelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of
768 vitamin D and calcium supplementation on falls: a randomized controlled trial.
769 vol. 18. 2003. doi:10.1359/jbmr.2003.18.2.343.
- 770 [52] Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig
771 H. Effects of a long-term vitamin D and calcium supplementation on falls and
772 parameters of muscle function in community-dwelling older individuals.
773 *Osteoporos Int* 2009;20:315–22. doi:10.1007/s00198-008-0662-7.

- 774 [53] Corless D, Evans SJW, Boucher BJ. Do vitamin D supplements improve the
775 physical capabilities of elderly hospital patients? *Age Ageing* 1985;14:76–84.
- 776 [54] Dhesi JK, Jackson SHD, Bearne LM, Moniz C, Hurley M V, Swift CG, et al.
777 Vitamin D supplementation improves neuromuscular function in older people
778 who fall. *Age Ageing* 2004;33:589–95. doi:10.1093/ageing/afh209.
- 779 [55] Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular
780 atrophy and reduces falls and hip fractures in women after stroke: a
781 randomized controlled trial. *Cerebrovasc Dis* 2005;20:187–92.
782 doi:10.1159/000087203.
- 783 [56] Witham MD, Crichton LJ, Gillespie ND, Struthers AD, McMurdo MET. The
784 effects of vitamin D supplementation on physical function and quality of life in
785 older patients with heart failure: a randomized controlled trial. *Circ Heart Fail*
786 2010;3:195–201. doi:10.1161/CIRCHEARTFAILURE.109.907899.
- 787 [57] Zhu K, Austin N, Devine A, Bruce D, Prince RL. A randomized controlled trial
788 of the effects of vitamin D on muscle strength and mobility in older women with
789 vitamin D insufficiency. *J Am Geriatr Soc* 2010;58:2063–8. doi:10.1111/j.1532-
790 5415.2010.03142.x.
- 791 [58] Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID. A
792 Randomized, Controlled Trial of Quadriceps Resistance Exercise and Vitamin
793 D in Frail Older People: The Frailty Interventions Trial in Elderly Subjects
794 (FITNESS). *J Am Geriatr Soc* 2003;51:291–9. doi:10.1046/j.1532-
795 5415.2003.51101.x.
- 796 [59] Smedshaug GB, Pedersen JI, Meyer HE. Can vitamin D supplementation
797 improve grip strength in elderly nursing home residents? A double-blinded

- 798 controlled trial. *Scand J Food Nutr* 2007;51:74–8.
799 doi:10.1080/03461230701422528.
- 800 [60] Björkman MP, Finne-Soveri H, Tilvis RS. Whey protein supplementation in
801 nursing home residents. A randomized controlled trial. *Eur Geriatr Med*
802 2012;3:161–6. doi:10.1016/j.eurger.2012.03.010.
- 803 [61] Carlsson M, Littbrand H, Gustafson Y, Lundin-Olsson L, Lindelöf N, Rosendahl
804 E, et al. Effects of high-intensity exercise and protein supplement on muscle
805 mass in ADL dependent older people with and without malnutrition—A
806 randomized controlled trial. *J Nutr Health Aging* 2011;15:554–60.
807 doi:10.1007/s12603-011-0017-5.
- 808 [62] Arnarson A, Gudny Geirsdottir O, Ramel A, Briem K, Jonsson P V, Thorsdottir
809 I. Effects of whey proteins and carbohydrates on the efficacy of resistance
810 training in elderly people: double blind, randomised controlled trial. *Eur J Clin*
811 *Nutr* 2013;67:821–6. doi:10.1038/ejcn.2013.40.
- 812 [63] Chale A, Cloutier GJ, Hau C, Phillips EM, Dallal GE, Fielding RA. Efficacy of
813 whey protein supplementation on resistance exercise-induced changes in lean
814 mass, muscle strength, and physical function in mobility-limited older adults.
815 *Journals Gerontol - Ser A Biol Sci Med Sci* 2013;68:682–90.
816 doi:10.1093/gerona/gls221.
- 817 [64] Verdijk LB, Jonkers RAM, Gleeson BG, Beelen M, Meijer K, Savelberg HHCM,
818 et al. Protein supplementation before and after exercise does not further
819 augment skeletal muscle hypertrophy after resistance training in elderly men.
820 *Am J Clin Nutr* 2009;89:608–16. doi:10.3945/ajcn.2008.26626.
- 821 [65] Leenders M, Verdijk LB, van der Hoeven L, van Kranenburg J, Hartgens F,

- 822 Wodzig WKWH, et al. Prolonged leucine supplementation does not augment
823 muscle mass or affect glycemic control in elderly type 2 diabetic men. *J Nutr*
824 2011;141:1070–6. doi:10.3945/jn.111.138495.
- 825 [66] Verhoeven S, Vanschoonbeek K, Verdijk LB, Koopman R, Wodzig WKWH,
826 Dendale P, et al. Long-term leucine supplementation does not increase muscle
827 mass or strength in healthy elderly men. *Am J Clin Nutr* 2009;89:1468–75.
828 doi:10.3945/ajcn.2008.26668.
- 829 [67] Trabal J, Forga M, Leyes P, Torres F, Rubio J, Prieto E, et al. Effects of free
830 leucine supplementation and resistance training on muscle strength and
831 functional status in older adults: A randomized controlled trial. *Clin Interv Aging*
832 2015;10:713–23. doi:10.2147/CIA.S75271.
- 833 [68] Del Favero S, Roschel H, Solis MY, Hayashi AP, Artioli GG, Otaduy MC, et al.
834 Beta-alanine (Carnosyn™) supplementation in elderly subjects (60-80 years):
835 Effects on muscle carnosine content and physical capacity. *Amino Acids*
836 2012;43:49–56. doi:10.1007/s00726-011-1190-x.
- 837 [69] Solerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, Basso C, et
838 al. Nutritional supplements with oral amino acid mixtures increases whole-body
839 lean mass and insulin sensitivity in elderly subjects with sarcopenia. *Am J*
840 *Cardiol* 2008;101:69E–77E. doi:10.1016/j.amjcard.2008.03.004.
- 841 [70] Flakoll P, Sharp R, Baier S, Levenhagen D, Carr C, Nissen S. Effect of ??-
842 hydroxy-??-methylbutyrate, arginine, and lysine supplementation on strength,
843 functionality, body composition, and protein metabolism in elderly women.
844 *Nutrition* 2004;20:445–51. doi:10.1016/j.nut.2004.01.009.
- 845 [71] Scognamiglio R, Piccolotto R, Negut C, Tiengo A, Avogaro A. Oral amino

- 846 acids in elderly subjects: effect on myocardial function and walking capacity.
847 Gerontology 2005;51:302–8. doi:10.1159/000086366.
- 848 [72] Ferrando AA, Paddon-Jones D, Hays NP, Kortebein P, Ronsen O, Williams
849 RH, et al. EAA supplementation to increase nitrogen intake improves muscle
850 function during bed rest in the elderly. Clin Nutr 2010;29:18–23.
851 doi:10.1016/j.clnu.2009.03.009.
- 852 [73] Rosendahl E, Lindelöf N, Littbrand H, Yifter-Lindgren E, Lundin-Olsson L,
853 Håglin L, et al. High-intensity functional exercise program and protein-enriched
854 energy supplement for older persons dependent in activities of daily living: A
855 randomised controlled trial. Aust J Physiother 2006;52:105–13.
- 856 [74] Tieland M, Borgonjen-Van den Berg KJ, van Loon LJC, de Groot LCPGM.
857 Dietary protein intake in community-dwelling, frail, and institutionalized elderly
858 people: scope for improvement. Eur J Nutr 2012;51:173–9.
859 doi:10.1007/s00394-011-0203-6.
- 860 [75] Fujita T. Reappraisal of Katsuragi calcium study, a prospective, double-blind,
861 placebo-controlled study of the effect of active absorbable algal calcium
862 (AAACa) on vertebral deformity and fracture. J Bone Miner Metab 2004;22:32–
863 8.
- 864 [76] Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation
865 in elderly people at risk from malnutrition. Cochrane Database Syst Rev
866 2009:CD003288. doi:10.1002/14651858.CD003288.pub3.
- 867 [77] Komar B, Schwingshackl L, Hoffmann G. Effects of leucine-rich protein
868 supplements on anthropometric parameter and muscle strength in the elderly:
869 a systematic review and meta-analysis. J Nutr Health Aging 2015;19:437–46.

- 870 doi:10.1007/s12603-014-0559-4.
- 871 [78] Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al.
872 Evidence-based recommendations for optimal dietary protein intake in older
873 people: A position paper from the prot-age study group. *J Am Med Dir Assoc*
874 2013;14:542–59. doi:10.1016/j.jamda.2013.05.021.
- 875 [79] Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Effectiveness of
876 Nutritional Supplementation on Muscle Mass in Treatment of Sarcopenia in
877 Old Age: A Systematic Review. *J Am Med Dir Assoc* 2013;14:10–7.
878 doi:10.1016/j.jamda.2012.08.001.
- 879 [80] Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, et al. Effects of
880 exercise and amino acid supplementation on body composition and physical
881 function in community-dwelling elderly Japanese sarcopenic women: A
882 randomized controlled trial. *J Am Geriatr Soc* 2012;60:16–23.
883 doi:10.1111/j.1532-5415.2011.03776.x.
- 884 [81] Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW,
885 Theiler R, et al. Monthly High-Dose Vitamin D Treatment for the Prevention of
886 Functional Decline: A Randomized Clinical Trial. *JAMA Intern Med* 2016:1–10.
887 doi:10.1001/jamainternmed.2015.7148.
- 888 [82] Muir SW, Montero-Odasso M. Effect of vitamin D supplementation on muscle
889 strength, gait and balance in older adults: a systematic review and meta-
890 analysis. *J Am Geriatr Soc* 2011;59:2291–300. doi:10.1111/j.1532-
891 5415.2011.03733.x.
- 892 [83] de Goede J, Geleijnse JM, Ding EL, Soedamah-Muthu SS. Effect of cheese
893 consumption on blood lipids: a systematic review and meta-analysis of

- 894 randomized controlled trials. *Nutr Rev* 2015;73:259–75.
895 doi:10.1093/nutrit/nuu060.
- 896 [84] Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly
897 people at risk from malnutrition. *Cochrane Database Syst Rev* 2005.
- 898 [85] Reid IR, Horne A, Mason B, Ames R, Bava U, Gamble GD. Effects of Calcium
899 Supplementation on Body Weight and Blood Pressure in Normal Older
900 Women: A Randomized Controlled Trial. *J Clin Endocrinol Metab*
901 2005;90:3824–9. doi:10.1210/jc.2004-2205.
- 902 [86] Smidt LJ, Cremin FM, Grivetti LE, Clifford AJ. Influence of thiamin
903 supplementation on the health and general well-being of an elderly Irish
904 population with marginal thiamin deficiency. vol. 46. 1991.
- 905 [87] Schürch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein
906 supplements increase serum insulin-like growth factor-I levels and attenuate
907 proximal femur bone loss in patients with recent hip fracture. A randomized,
908 double-blind, placebo-controlled trial. *Ann Intern Med* 1998;128:801–9.
- 909




Fig. 1 Dietary protein increases serum levels of amino acids and IGF-I. Amino acids are the most potent activators of mTOR, that stimulate muscle protein synthesis and hence hypertrophy, and consequently muscle strength. Increases in serum IGF-I also stimulates the renal production of 1,25(OH)D₃. IGF-I insulin-like growth factor-I; mTOR, mammalian target of rapamycin; 1,25(OH)D₂D₃, 1,25-dihydroxyvitamin-D₃. Adopted from Bonjour et al. 2007 and Rizzoli et al. 2014 [30,31]

Table 1. Inclusion and exclusion criteria for including studies in the systematic review

	Inclusion	Exclusion
POPULATION	<ul style="list-style-type: none"> • Adults aged 55 years or older 	<ul style="list-style-type: none"> • Animal studies • Children • Pregnancy or lactating • Athletes / body builders • Renal dysfunction
INTERVENTION	<ul style="list-style-type: none"> • Randomized double-blind, placebo-controlled trials • Dairy, or dairy specific components (not mandatory to be dairy-based) • Vitamin D 	<ul style="list-style-type: none"> • Dietary counseling only • Nutritional supplementation products that also give other micronutrients that are not present in dairy • Regular or usual care as reference in case intervention consisted of supplement • Small amounts of intervention component where there could not be an expected effect based on outcomes relevant for this review and meta-analysis
OTHER	<ul style="list-style-type: none"> • Articles written in English • Full text articles only 	<ul style="list-style-type: none"> • Reviews • Conference articles • Letters • Notes • Short surveys • Editorials • Book chapter • Duplicate publications

Table 2. Quality assessment criteria and scored risk of bias table.

A: Was the assigned treatment adequately concealed prior to allocation?

- 3= Method did not allow disclosure of assignment
- 2= Small but possible chance of disclosure of assignment
- 1= States random, but no description or quasi-randomized

B1: Were all randomized participants accounted for?

- 3 = Yes
- 2 = Partial description; some uncertainty
- 1 = Inadequate detail

B2: How many participants were lost to follow-up or otherwise excluded from the analysis?

- 3= 0-10%
- 2=>10-20%
- 1= >20%

C: Were the outcome assessors blinded to treatment status?

- 3= Effective action taken to blind assessors
- 2= Small or moderate chance of unblinding of assessors
- 1= Not mentioned or not possible

D: Were the treatment and control group comparable at entry?

- 3= Good comparability of groups, or confounding adjusted for in analysis
- 2= Confounding small; mentioned but not adjusted for
- 1= Large potential for confounding, or not discussed

E: Were the subjects blind to assignment status after allocation?

- 3= Effective action taken to blind subjects
- 2= Small or moderate chance of unblinding of subjects
- 1= Not possible, or not mentioned (unless double-blind), or possible, but not done

F: Were the treatment providers blind to assignment status?

- 3= Effective action taken to blind treatment providers
- 2= Small or moderate chance of unblinding of treatment providers
- 1= Not possible, or not mentioned, or possible, but not done

G: Were the inclusion and exclusion criteria clearly defined?

- 3= Clearly defined
- 2= Poorly defined
- 1= Not defined

H: Were the outcome measures used clearly defined?

- 3= Clearly defined
- 2= Poorly defined
- 1= Not defined

J: Was ascertainment of the outcomes reliable?

- 3= "Golden standard" was used to measure outcome
- 2= Validated method, but not the "golden standard"
- 1= Not possible, or not mentioned, or possible, but not done

K: Was the duration of surveillance clinically appropriate?

- 3= 6 months or more
 - 2= 3 months to less than 6 months
 - 1= Less than 3 months or not defined
-




Fig. 2 Flow-chart of article selection for systematic reviewing and meta-analysis

Table 3: Overview of studies included in the systematic review and meta-analysis.

Reference (primary author and year)	Study population; age; mean (range); place of study	Intervention	Compliance	Treatment duration	Outcome measurements	Effect on outcome
Björkman 2012 [60]	103 men and women from a single center municipal nursing home; age: 83.5±8.2 y; Helsinki, Finland.	20 g protein in 4.5 dL of juice/day for test group. 45 kcal of energy, 11 g carbohydrates, 1 g fiber, and 40 mg of vitamin C/ dl in test drink and placebo drink without protein.	Intervention group: 81.8±18.1%, Control: 73.9±24.8% (P = 0.263)	6 months	HGS, Body Weight (BW), Fat-Free Mass (FFM), Mini Nutritional Assessment (MNA) and Improved MNA score.	Weight showed a higher mean change over 6 months-period compared to the control group. The mean change of FFM, and HGS between the two groups did not differ significantly.
Reid 2005 [85]	1471 healthy women who are ≥5y post-menopausal and ≥55y; Intervention: 74.2±4.2, placebo: 74.3±4.3.	1 g elemental calcium daily (in form of 2 tablets in morning and 3 tablets in the evening) as citrate or identical placebo.	Intervention: 78%; Control: 80% (= 0.26)	30 months	BW, BMI, Fat Mass (FM), and Lean Body Mass (LBM) (DXA).	Weight decreased in both groups, but the difference was not significant (P=-0.93). Fat and LBM did not show an effect of calcium.
Bunout 2006 [42]	48 healthy older adults living in the community; 76 ± 4 y; Chili.	Daily, vitamin D3 (vitamin D3) 400 IU + 800 mg calcium or calcium alone as control.	92±3% in both intervention and control group.	9 months	Body composition: Lean Mass (LM), FM, arm circumference, waist circumference, hip circumference, HGS, general physical fitness (TUG) and physical performance (Short Physical Battery=SPPB).	Gait speed increased in supplementation group (whether trained or not) than in non-supplemented subjects (P = 0.02). No significant changes were found in weight, circumferences or body composition in any of the four groups.
Carlson 2011 [61]	94 people; 65-99 y with severe physical or cognitive impairments, and living in residential care facilities; Umeå, Northern Sweden.	2x2 factorial model exercise intervention compared with a control activity and an intake of a protein-enriched drink (200 ml) compared to a placebo. The intervention drink contained 7.4 g protein, 15.7 g carbohydrate, and 0.43 g fat; the placebo drink contained 0.2 g protein and 10.8 g carbohydrate. Subjects got the drink 5 times per two weeks.	Protein drink: 84%; placebo: 79%. The protein Drink package was completely taken in on 82% and the placebo drink on 80%.	3 months	Body composition (FFM, Intra Cellular Water=ICW, BW), BMI and Berg Balance Scale.	No significant differences in ICW, muscle mass, BW, Berg Balance scale in the protein group compared to the placebo group after 3 months or 6 months. The within group analyses in people with MNA ≤17 showed no significant changes in ICW and BW either in exercise group (0.9 l, p = 0.410 vs -0.9 kg, p = 0.185) or in control group (0.3 l, p = 0.673 vs -0.5 kg, p = 0.548).

Ceglia 2013 [39]	21 ambulatory, community-dwelling, postmenopausal women 78±5yrs.	Daily oral vitamin D3 capsule (4000 IU) or matching placebo.	No information	4 months	SPPB	No changes in total SPPB score by group (P= 1.0).
Corless 1985 [53]	65 patients in the geriatric wards of four hospitals; intervention: 82.6 y (6.9) mean (SEM), placebo: 82.3 y (6.0); England.	9000 unit's vitamin D2 or identical looking placebo.	Intervention group showed no significant increase in serum vitamin D at follow-up, suggesting low compliance.	2 months	Muscle function score.	No significant differences were found for muscle function between the two groups before or at any time during the trial.
Dawson-Hughes 1991 [47]	246 postmenopausal women; intervention: 61.4±0.5 y, placebo: 61.9±0.5 y; USA.	400 IU vitamin D + 127 mg calcium (calcium phosphate) or placebo with 127 mg calcium. Additionally, all subjects received 250 mg elemental calcium (calcium citrate).	Compliance was 99%.	12 months	Fat%, LBM, and muscle strength.	There was no change or effect of vitamin D supplementation on whole-body fat or lean-tissue mass during the study. Muscle strength did not differ between the groups during both periods.
Dhesi 2004 [54]	123 elderly men and women attending a falls clinic and with 25OHD levels ≤12 µg/l and normal bone biochemistry; intervention group: 77.0±6.3 y, placebo group: 76.6±6.1 y; London, UK.	Single intramuscular injection of 600,000 IU vitamin D2.	High compliance due to single injection of vitamin D2.	6 months	Functional performance (Aggregate Functional Performance Time (AFPT)): 50 ft. walk, rising from a 42-cm high chair.	The placebo group showed a 6.6 s deterioration in AFPT over the trial period; treatment group improved by 2.0 s. This resulted in a significant difference in the change over 6 months between the two groups (P<0.01). Both groups showed a loss of strength over the trial period.
Gallagher 2013 [45]	STOP IT: 488 elderly women; 71±4 y; USA.	Twice daily, 0.25 mcg calcitriol, conjugated estrogens 0.625 mg daily, a combination of both or placebo.	No information.	3 years	Body composition: total and regional fat and LBM (DXA).	No significant effect of calcitriol on total body fat (p=0.572) but a significant decrease in LBM at the end of the 3-year study (p<0.0001) in both groups (placebo and calcitriol) was found. In the placebo group, there was a significant decrease in LBM (p<0.0001) but not in total FM (p =0.628). There was no difference between the placebo and calcitriol groups in percent body FM (p = 0.410) or LBM (p = 0.921) at the end of the 3-year study.
Janssen 2010 [48]	59 women with serum 25OHD levels between 20-50 nmol/L, attending an outpatient clinic of the De-	Daily 400 IU vitamin D (vitamin D3) +500 mg/day calcium, or identical placebo tablets + calcium 500 mg/day.	59-100% (average 94.8%).	6 months	BW, HGS, Timed "Get Up and Go" test (TGUG) and habitual physical activity.	No significant difference was found between the two groups at 6 months in HGS. In the analysis of variance, with handgrip strength as outcome, the intervention did not affect muscle strength compared to placebo significantly.

	partment of Geriatric Medicine; intervention group: 82.4±6.4 y, placebo group: 79.2±6.7y; Utrecht.					
Kenny 2003 [49]	65 healthy, community-dwelling men; 76.7±4 y (65–87); Connecticut, USA.	Daily vitamin D3 (1,000 IU/d) + 500 mg calcium or a matching placebo pill with 500 mg calcium.	No information.	6 months	Handgrip strength, physical performance (ability to rise from a chair, static balance and the 8-foot walk, the timed “up and go” test, and the timed “supine to stand” test).	Time effects for handgrip strength and timed supine to stand, were seen, but there was no time-by-group effect for any of these measures.
Leenders 2011 [65]	57 elderly males with type 2 diabetes; 71±1 yr; Wageningen, The Netherlands.	2.5 g L-leucine or placebo after each main meal.	No information.	6 months	Body composition (DXA): BW, LM, FM, regional leg mean mass, leg FM, fat percentage.	Lean tissue mass did not change or differ between groups and any time point (0, 3 and 6 months). Also, no changes were found in body fat percentage.
Lips 2010 [43]	213 men and women with insufficient vitamin D serum values (≤50 but ≥15 nmol/L); placebo: 77.6±6.6 y, intervention: 78.5±6.2 y; North America and Europe.	3 tablets once per week containing a placebo or 2800 IU vitamin D3. Only for those with a daily dietary calcium intake <1000 mg, 500 mg elemental calcium was prescribed.	No information.	4 months	SPPB: balance tests, gait speed test (timed 4-m walk) and timed rising from a chair and sitting for 5 repetitions.	After 16 weeks, SPPB did not differ significantly between treatment groups.
Moreira-Pfimer 2009 [50]	51 institutionalized living in two different long-stay geriatric care (LSGC) units; median age: 77.6, range 62–94 years; São Paulo, Brazil.	Daily calcium plus monthly placebo (calcium/placebo group) or daily calcium plus oral vitamin D3 (150,000 IU once a month during the first 2 months, followed by 90,000 IU once a month for the last 4 months (calcium/vitamin D group).	High	6 months	Maximum isometric strength of hip flexors (SHF) and knee extensors (SKE).	The placebo group showed no improvement in SHF and SKE at 6 months (p = 0.93 and p = 0.61, respectively), SHF and SKE was increased in the intervention group (p=0.0001 and p=0.0007).
Fujita 2004 [75]	58 hospitalized elderly women; group A: 80±6 y, group B 83±6 y and group C: 79±9 y; Osaka, Japan.	Group A got 900 mg/day Ca supplement as AAA Ca, group B got 900 mg/day Ca supplement in de form CaCO3 and group C got the placebo. Participants were instructed to take two capsules after each meal	No information	2 years	Whole body mass, fat content, lean content measured by DXA and BW.	Whole body mass, lean content expressed as a percentage of whole body mass, remained the same in the three groups. However, increase of fat content was significantly decreased in group A compared to group C, but not in group B compared to group C.

		daily.				
Smedshaug 2007 [59]	60 nursing home residents; mean age of 85 y;	Intervention group: 5 ml cod liver oil p/d containing 10 mg vitamin D3; The control group received 5 ml cod liver oil p/d without vitamin D.	No information	1 year	Grip strength	Grip strength did not improve in the vitamin D group (0.4 kg increase) compared with the control group (1.6 kg increase) after 1 year vitamin D supplementation (p=0.22).
Solerte 2008 [69]	41 consecutive elderly outpatients with sarcopenia and reduced whole-body lean body mass; age range: 66–84 y; Italy.	The oral AA mixture and an isocaloric placebo were ingested as snacks at 10:00 AM and 5:00 PM. The AA preparation (70.6 kcal/day) contained 8 g/day of AAs (L-leucine, 2.5 g; L-lysine, 1.3 g; L-isoleucine, 1.25 g; L-valine, 1.25 g; L-threonine, 0.7 g; L-cysteine, 0.3 g; L-histidine, 0.3 g; L-phenylalanine, 0.2 g; L-methionine, 0.1 g; L-tyrosine, 0.06 g; and L-tryptophan, 0.04 g). The trial had a cross-over design.	No information	18 months	Mean whole-body mass, BMI, FM	Mean values of BMI significantly increased in the AAs group (p=0.05) and in the placebo group (p=0.01); whereas the total body FM remained unchanged throughout the study. Whole-body LBM increased significantly after six months and more consistently after 18 months of oral nutritional supplementation with AAs
Rosendahl 2006 [73]	86 elderly dependent in activities of daily living; intervention group: 82.9±6.4 y, placebo group 85.6±7.0 y; Umeå Sweden.	Milk-based nutrient drink (200 ml) that contained 7.4 g protein, 15.7 g carbohydrate, and 408 kJ per 100 g. The placebo drink (200 ml) contained 0.2 g protein, 10.8 g carbohydrate, and 191 kJ per 100 g. This study had a 2x2 factorial design with exercise as an intervention and a control activity.	The protein-enriched energy supplement: 82%; placebo drink: 78%. Package completely emptied: 80%.	6 months	Berg Balance Scale, 2.4 meters timed test, and modified chair-stand test.	Berg Balance Scale, self-paced and maximum gait speed were followed-up at three and six months. No interaction effects were seen between the exercise and nutrition interventions. There was a significant difference in self-paced gait speed in favor of the placebo group at six months compared to the nutrition intervention group. For other outcomes, there was no significant effect for both the intervention group and placebo group.
Sato 2005 [55]	96 elderly women who were hospitalized stroke patients with hemiplegia; Placebo	Daily dose of 1,000 IU vitamin D2 or placebo.	No information.	2 years	Muscle strength and muscle biopsy.	Increases in the relative number and size of type II muscle fibers and improved muscle strength was found in the vitamin D-treated group compared with the placebo group. Type I fibers was not dif-

	group: 74.2±4.1 y, Intervention group: 74.1±3.9 y; Japan.					ferent in the intervention group compared to the placebo group.
Tieland, van de Rest 2012 [41]	61 prefrail and frail elderly; placebo: 81±1 y, intervention: 78±1 y; The Netherlands.	Daily, either 2 times beverages (250 mL) containing 15 g protein (milk protein concentrate, 7.1 g lactose, 0.5 g fat, and 0.4 g calcium), or a matching placebo containing no protein, 7.1 g lactose, and 0.4 g calcium.	92%	6 months	Skeletal muscle mass, FM, BW, HGS and physical performance (SPPB).	Skeletal muscle mass did not change in the intervention or placebo group during 6 months of intervention. Physical performance improved significantly in the intervention group and did not change in the placebo group. HGS did not significantly differ in the intervention group compared to the placebo group at the end of the intervention.
Witham 2010 [56]	91 elderly patients with systolic heart failure and 25-hydroxy vitamin D level of <50 nmol/L (20 ng/mL); placebo group: 80.6±5.7 y, intervention group: 78.8±5.6 y; UK.	Oral dose (100 000 IU vitamin D2 or placebo) was administered after baseline outcome measures and again after 10 weeks.	High	5 months	6-minute walk test, TUG-test and daily physical activity Levels.	The 6-minute walk test, TUG-test and daily activity did not significantly improve in the treatment group relative to placebo.
Zhu 2010 [57]	261 community-dwelling ambulant elderly women with serum 25-hydroxyvitamin D concentrations <24 ng/mL; placebo group: 77.0 ±4.8 y, intervention group: 76.8±4.2 y; Perth, Australia.	Vitamin D2 1,000 IU/d or identical placebo; calcium citrate (1 g calcium/d) in both groups	Vitamin D group: 86.7%; placebo group: 86.8%.	1 year	TUG-test.	In the lowest tertile, vitamin D improved TUAG more than calcium alone (P=0.05).
Bischoff 2003 [51]	62 elderly women in long-stay geriatric care; 85.3 y (63-99 y); Switzerland.	Daily 2 tablets containing 600 mg calcium carbonate and 400 IU vitamin D3 per tablet or 2 tablets containing 600 mg calcium carbonate.	Out of 89 participants, ten had a decreasing compliance.	3 months	TUG-test, and grip strength.	Musculoskeletal function improved significantly in CAL+D-group compared to CAL-group (No P-value for TUG was published).
Del Favero 2012 [68]	18 healthy older adults; Intervention group: 65±4 y, placebo group: 64±7 y; Sao Paolo, Brazil.	3.2 g beta-alanine (2 tablets x 800 mg given twice per day after lunch and dinner) or an identical placebo	100% (self-reported)	3 months	Muscle function test (timed stands and TUG-test) and physical functioning.	No significant changes between intervention and placebo group was observed for the timed stands and TUG-test after beta-alanine supplementation when compared to the placebo group.

Flakoll 2004 [70]	29 women recruited from senior citizen centers and adult assisted-living and care facilities; 81.1±1.8 y.	Orange drink, which contained HMB (Calcium HMB, 2 g), arginine (5 g), LYS (lysine Hall, 1.5 g) and ascorbic acid (0.5 g) in 8 oz. of water (HMB/ARG/LYS. In S1, the placebo group conceived: orange-flavored isocaloric drink of maltodextrin and ascorbic acid (0.5 g) in 8 oz. of water.	100%	3 months	Functionality (“get-up-and-go” performance test, body composition (body fat% and FFM, trunk circumference (abdomen and hip), limb circumference (arm, forearm, and thigh) and trunk circumference (abdomen and hip).	The HMB/ARG/LYS-supplemented subject’s significantly improved get-up-and-go performance times compared to the placebo group. Although not statistically different, the HMB/ARG/LYS group had an increase in fat-free mass, whereas subjects taking placebo showed a decrease in fat-free mass. FM and percentage of body fat were unchanged in both groups.
Pfeifer 2009 [52]	242 healthy ambulatory elderly women and men; Bad Pyrmont, Germany and Graz, Austria.	Daily, one tablet containing 400 IU vitamin D3 and 500 mg of elemental calcium (calcium carbonate) or one tablet with 500 mg at breakfast and dinner together with the meals.	No information.	12 months	TUG	Significant improvements in timed-up-and-go test after 12 months in the calcium + vitamin D group.
Scognamiglio 2005 [71]	95 healthy elderly subjects with reduced physical activity; AA-group: 74±6 y, placebo group: 74± 5 y; Italy.	12 g of AAs plus and 12.21 g of glucose, or placebo containing 12.21 g of glucose at 10.00 a.m., 4.00 p.m. and 10.00 p.m. The composition of the AA mixture (g/day): L-leucine 3.8, L-lysine 2, L-isoleucine 1.9, L-valine 1.9, L-threonine 1.1, L-cysteine 0.4, L-histidine 0.4, L-phenylalanine 0.3, L-methionine 0.2, L-tyrosine 0.1, and L-tryptophan 0.1.	Intervention: 86%; placebo: 87%	3 months	BMI, 6-min walk test.	BMI did not change significantly with intervention. The 6-min walk distance increased significantly in the AA-group, but not in the placebo group.
Smidt 1991 [86]	80 healthy older adult’s women selected from medical registration lists provided by the Southern Health Board of Ireland; Cork City, Republic of Ireland	Thiamin-supplemented (10 mg daily) or placebo.	95%	6 weeks	BW.	BW did not differ between the two groups during baseline and treatment, and there were no difference in mean values when comparing baseline and treatment for the placebo group. In the thiamin supplemented group, mean BW increased significantly during treatment compared to baseline values. Energy intake also increased significantly in the intervention group, but not in the placebo

						group.
Verhoeven 2009 [66]	29 healthy elderly men; 71±4 y; The Netherlands.	2.5 g leucine or a placebo with each main meal (breakfast, lunch, and dinner).	No information.	3 months	BW, whole-body and leg LBM, FM and leg fat.	Whole-body, leg FM, fat-free mass (DXA), did not differ between groups before the intervention. No changes in body composition or muscle mass were observed over time, and no significant differences were observed between groups.
Verdijk 2009 [64]	26 healthy elderly men; 72±2 in both groups; The Netherlands	Resistance-type exercise training with protein supplement (3 sessions/week, 20 grams protein per session) or placebo.	No information	3 months	BMI, BW, leg mean mass, LM and FM.	Leg muscle mass, BMI and BW did not significantly differ from protein to placebo group.
Tieland, Dirks, 2012 [40]	62 frail older adults 78±1 y; The Netherlands.	Resistance-type exercise training (2 sessions/week) with daily protein supplement of 2 times 15 grams protein or placebo.	No information.	6 months	BW, LBM, FM, HGS, SPPB, gait speed, chair rise.	LBM increased significantly in the protein group compared to placebo group. Physical performance increased in both groups, with no interaction effect of dietary intervention.
Arnarson 2013 [62]	141 apparently healthy older adults; intervention group: 73.3 ±6 y, placebo group: 74.6 ±5.8 y (range: 65-91); Capital area of Iceland.	20 gram of whey protein or isocaloric placebo that was given 3 times per week during resistance exercise training.	No information.	3 months	LM, appendicular skeletal muscle mass, TUG, 6 min walk for distance.	No significant difference was found between the protein and placebo group after three months for LM, appendicular skeletal muscle mass, TUG, 6 min walk for distance.
Chalé 2013 [63]	75 mobility-limited older adults; age range 70-85 y; USA.	Daily 40 gram of whey protein or an isocaloric placebo powder was given to subjects, both in combination with high-intensity resistance training.	No information.	6 months	Body mass, LM, FM, chair-rise time, SPPB, and 400m walk.	No outcomes scored significantly higher in the intervention group compared to the placebo group over time.
Trabal 2015 [67]	30 older adults; Age: Leucine group: 85±8 y, Control group: 4±4; Barcelona, Spain	10 g/d of L-leucine or placebo (maltodextrin) and both groups had resistance training (3 times/week)	Intervention: 80%; placebo: 94%.	3 months	Physical Performance Battery (PPB): balance test, 4m walking speed test, 5 times chair rise test, and the TUG-test, MNA, BW, BMI, waist circumference, triceps skin fold, and calf circumference.	Mid-upper arm muscle area and TUG significantly improved in the intervention group compared to the placebo group. For the other outcomes, no significant between-group differences were found.
Ferrando 2010 [72]	22 older adults; Age: control: 68±5 y, Intervention: 71±6.72 y;	3 times per day 15 g of EEA or placebo during constant bed rest (except	No information.	10 days	LM, leg LM, FM.	No significant effect of EAA on total or leg LM, FM, body mass.

	USA.	when toileting).				
Schürch 1998 [87]	82 orthopedic ward patients; 80.7±7.4 y;	550 mg/d calcium and one dose at baseline of vitamin D (200000 IU) for all patients and 20 g/d protein (90% milk proteins) or placebo. Both powders contained: vitamin A (1000 IU), vitamin K, (30 µg), vitamin C (20 mg), calcium (550 mg), magnesium (91 mg), phosphorus (429 mg), and sodium (228 mg).	No information.	6 months	Muscle strength, BW, LM, FM and HGS.	No significant between-group differences were found for biceps muscle strength, BW, LM, FM and hand grips strength.

Table 4. Risk of bias scores per trial.

Reference	A	B1	B2	C	D	E	F	H	J	K	L
Bjorkman 2012 [55]	2	2	3	3	3	3	3	3	3	3	3
Reid 2005 [80]	2	2	2	1	3	3	2	3	3	3	3
Bunout 2006 [37]	3	3	3	2	3	3	2	3	3	2	3
Carlsson 2011 [61]	2	3	2	1	3	2	1	3	3	2	2
Ceglia 2013 [39]	1	3	2	2	3	2	2	3	3	3	2
Dawson-Hughes 1991 [47]	2	2	2	2	3	3	2	2	3	2	3
Dhesi 2004 [54]	3	3	2	2	3	3	3	3	2	2	3
Gallagher 2013 [45]	2	3	3	2	3	3	3	3	3	1	3
Janssen 2010 [48]	2	2	2	2	3	3	2	2	3	2	3
Kenny 2003 [49]	2	3	3	2	2	3	2	2	2	2	3
Leenders 2011 [65]	2	3	3	2	3	3	2	3	3	3	3
Lips 2010 [43]	2	2	2	2	2	3	2	3	3	2	2
Moreira-Pfrimer 2009 [50]	3	3	2	2	3	3	2	3	3	2	3
Fujita 2004 [75]	2	1	1	2	3	3	2	2	2	3	3
Smedshaug 2007 [59]	2	2	3	2	3	3	2	3	3	2	3
Solerte 2008 [69]	2	1	1	1	1	2	1	1	2	3	3
Rosendahl 2006 [73]	3	2	2	2	2	3	2	2	3	2	3
Sato 2005 [55]	2	3	2	2	3	3	2	3	3	3	3
Tieland 2012 [41]	3	3	3	3	3	3	3	3	3	2	3
Witham 2010 [56]	2	3	3	3	3	3	3	3	2	2	2
Zhu 2010 [57]	2	2	2	3	3	3	3	3	3	2	3
Bischoff 2003 [51]	3	2	1	3	3	3	3	3	3	2	2
Del Favero 2012 [68]	2	3	3	2	3	3	2	3	3	2	2
Flakoll 2004 [70]	2	3	2	2	3	3	2	3	2	2	2
Pfeifer 2009 [52]	2	3	3	2	3	3	2	3	3	2	3
Scognamiglio 2005 [71]	2	2	3	2	3	3	2	3	3	2	2
Smidt 1991 [86]	2	3	3	2	3	3	2	3	3	2	1
Verhoeven 2009 [66]	2	3	3	2	3	3	2	2	2	2	2
Verdijk 2009 [64]	2	3	3	2	3	2	2	2	3	2	1
Tieland, Dirks 2012 [40]	3	3	2	3	3	3	3	3	3	2	3
Arnarson 2013 [62]	3	2	3	3	3	3	3	2	3	2	2
Chalé 2013 [63]	2	2	3	2	3	3	3	3	3	2	3
Trabal (2015) [67]	2	2	1	3	3	3	3	2	3	2	2
Ferrando (2010) [72]	2	2	2	1	3	3	1	3	3	2	1
Schürch (1998) [87]	2	2	1	2	3	3	2	3	3	2	3

Letters and scores are assigned to a quality assessment question and explanation of the score which are displayed in Table 2




Fig.3 Meta-analysis of the effect of protein and amino acids on body weight (kg)





Fig. 4. Meta-analysis of the effect of protein supplementation (during ten days to six months) on lean body mass (kg)



Bunout-A= no training, Bunout-B= training

Fig. 5 Meta-analysis of the effect of vitamin D3 on leg strength






Fig. 6 Meta-analysis of the effect of protein on leg strength.



Bunout 2006-A: no exercise intervention in both groups; Bunout 2006-B: with exercise intervention in both groups.

Fig. 7 Meta-analysis of the effect of vitamin D on hand grip strength (in kg).



Bunout 2006-A: no exercise intervention in both groups; Bunout 2006-B: with exercise intervention in both groups.

Fig. 8 Meta-analysis of the effect of vitamin D on physical performance.






Fig. 9 Meta-analysis of the effect of vitamin D on walking capacity.




Bunout 2006-A: no exercise intervention in both groups; Bunout 2006-B: exercise intervention in both groups.

Fig. 10 Meta-analysis of the effect of vitamin D supplementation on TUG (s).


Supplemental Material




Supplemental Figure S1. Funnel plot of protein supplementation trials on body weight




Supplemental figure S2. Subgroup analysis of the effect of protein supplementation on body weight.




Supplemental figure S3. Subgroup analysis of the effect of 6 months of protein and L-leucine supplementation on body weight.




Supplemental figure S4. Subgroup analysis of the effect ≥ 20 grams protein supplementation per day.




Supplemental figure S5. Subgroup analysis of the effect protein and L-leucine supplementation on body weight in “vulnerable older adults”.




Supplemental figure S6. Subgroup analysis of trials that included exercise-training (in both protein groups as in placebo group) and that study the effect of protein supplementation on body weight.



Supplemental figure S7. Sensitivity analysis (blinding of outcome assessors and treatment providers) of the effect of protein/amino acid (AA) supplementation on body weight.



Supplemental figure S8. Funnel plot of the effect of vitamin D supplementation on physical performance.



Bunout-A= no training, Bunout-B= training

Supplemental figure S9. Subgroup-analysis of the effect 400-1000 IU vitamin D on TUG.